| Patents for A61P 1 - Drugs for disorders of the alimentary tract or the digestive system (125,798) |
|---|
| 02/08/2006 | CN1729973A Kurarinone formulation and its preparation process |
| 02/08/2006 | CN1729972A Ornidazole buccal tablet and method for preparing the same |
| 02/08/2006 | CN1240836C Transforming growth factor alpha HI |
| 02/08/2006 | CN1240435C Chinese medicine and Hui medicine preparation for treating cholecystitis and its preparing method |
| 02/08/2006 | CN1240433C Traditional Chinese medicine compositions for weight reduction |
| 02/08/2006 | CN1240429C Chinese medicinal pill for conditioning internal injury caused by overstrain and asthenia |
| 02/08/2006 | CN1240426C Prepared Chinese medicine for treating ulcerative stomatitis |
| 02/08/2006 | CN1240418C Chinese compound medicine for treating gastrodynia and its preparation method |
| 02/08/2006 | CN1240413C Wind-fire toothache treating Chinese medicinal powder and its preparation process |
| 02/08/2006 | CN1240411C Traditional Chinese medicine for treating stomatitis |
| 02/08/2006 | CN1240409C Medicine for treating chronic hepatitis |
| 02/08/2006 | CN1240405C Oral liquid for treating deuteropathic weak and senile weak |
| 02/08/2006 | CN1240402C Application of wintersweet oil in preparation of medicine for treating digestive system disease |
| 02/08/2006 | CN1240398C Application of active biologics prepared turtle and/or tortoise organs and animal penis in preparing medicine |
| 02/08/2006 | CN1240392C Agent for promoting cell activation for external use |
| 02/08/2006 | CN1240390C Biologic converted ginseng composition and preparing process thereof |
| 02/08/2006 | CN1240372C Incorporation of exogenous lactic acid bacteria into oral microflora |
| 02/08/2006 | CN1240322C Composition and use |
| 02/07/2006 | US6995299 Model system for Hepatitis C virus infection in humans, comprising non-human animal rendered immunologically tolerant to human hepatocytes and subsequently transplanted with human hepatocytes and infected with Hepatitis C |
| 02/07/2006 | US6995272 Crystal form of N-(4-trifluoromethylphenyl)-5-methylisoxazole-4-carboxamide |
| 02/07/2006 | US6995184 Such as (7-chloro-2-methyl-1-(3-(methylsulphanyl)propyl)-1H-indol-3-yl)(2,3-dichloro-phenyl)methanone; cannabinoid receptors (cb2); G proteins coupled receptors |
| 02/07/2006 | US6995182 1-sulfonyl pyrrolidine derivatives |
| 02/07/2006 | US6995177 HCV NS3 protease inhibitors |
| 02/07/2006 | US6995176 1-heterocyclylalkyl-3-sulfonyl-indole or -indazole derivatives as 5-hydroxytryptamine-6 ligands |
| 02/07/2006 | US6995174 for inhibiting proteases |
| 02/07/2006 | US6995167 Arylkylamine spirofuropyridines useful in therapy |
| 02/07/2006 | US6995163 having an excellent corticotrophin-releasing-factor receptor antagonistic activity; for treating or preventing depression, nerve system disorders, schizophrenia, peptic ulcer, irritable bowel syndrome |
| 02/07/2006 | US6995161 Central nervous system disorders |
| 02/07/2006 | US6995159 4-piperazin-1-yl-2-(pyridin-2-ylmethoxy)-pyrimidine, 2-(6-methyl-pyridin-2-ylmethoxy)-4-piperazin-1-yl-pyrimidine, and 2-(6-chloro-pyridin-2-ylmethoxy)-4-piperazin-1-yl-pyrimidine; for treatment of seizure and eating disorders; reduced side effects |
| 02/07/2006 | US6995153 tachykinin receptor antagonist, in particular, an NK1 receptor antagonist; prophylactic or therapeutic agent against tachykinin receptor-related pathological conditions, including increased urinary frequency, incontinence, vomiting, inflammation |
| 02/07/2006 | US6995151 Isophthalic acid derivatives as matrix metalloproteinase inhibitors |
| 02/07/2006 | US6995133 invention describes reduced synthesis of IFN alpha 5 in livers of patients with hepatitis C in comparison to healthy livers; demonstrates importance of use of such interferon sub-types in fabricating compositions for treating viral hepatopathies |
| 02/07/2006 | US6994863 Pharmaceutical and cosmetic carrier and composition for topical application |
| 02/07/2006 | US6994859 Biologically active, hemagglutinin from type A Clostridium botulinum and methods of use |
| 02/07/2006 | US6994857 A Therapeutic protein (e.g., a polypeptide, antibody, or peptide, or fragments and variants) fused to albumin, is sufficient to prolong the shelf-lilfe of therapeutic protein |
| 02/07/2006 | CA2340202C Hydroxy pipecolate hydroxamic acid derivatives as mmp inhibitors |
| 02/07/2006 | CA2311344C 5-(2-imidazolinylamino)-benzimidazole derivatives, their preparation and their use as .alpha.-adrenoceptor agonists with improved metabolic stability |
| 02/07/2006 | CA2273479C 6-phenylpyridyl-2-amine derivatives useful as nos inhibitors |
| 02/07/2006 | CA2221075C Use of aminoalcohol derivatives in the treatment of liver disease |
| 02/02/2006 | WO2006011670A1 PYRROLO[2,3-c]PYRIDINE COMPOUND, PROCESS FOR PRODUCING THE SAME, AND USE |
| 02/02/2006 | WO2006011466A1 5-substituted-2-phenylamino-benzamide as mek inhibitor |
| 02/02/2006 | WO2002094990A3 Receptors and membrane-associated proteins |
| 02/02/2006 | US20060026700 Tissue specific genes and gene clusters |
| 02/02/2006 | US20060025597 4-(Aminomethyl)-2-(2,6-dioxo(3-piperidyl))isoindoline-1,3-dione hydrochloride; cytokines level reduced; tumor necrosis factor inhibitors; nontoxic; anticarcinogenic agents; antitumor agents (solid/blood-borne); cardiovascular disorders; osteoporosis; antiinflammatory agents; autoimmune diseases |
| 02/02/2006 | US20060025584 Crystallization of polyol compositions, crystalline polyol composition product and use thereof |
| 02/02/2006 | US20060025442 Acylated piperidine derivatives as melanocortin-4 receptor agonists |
| 02/02/2006 | US20060025432 N-[2-[(3-Chloro-2-fluorobenzyl)thio]-6-[(2-hydroxy-1-methylethyl)amino]-4-pyrimidinyl]- 4-morpholinesulfonamide; asthma, antiallergens; rhinitis, chronic obstructive pulmonary disease, inflammatory bowel disease, irritable bowel syndrome, osteoarthritis, osteoporosis, rheumatoid arthritis, psoriasis |
| 02/02/2006 | US20060025428 Bicyclic heteroaromatic compounds as kinase inhibitors |
| 02/02/2006 | US20060025423 2,3-Dichloro-N-(3-methoxy-5-methyl-2-pyrazinyl)-benzenesulphonamide; inflammatory diseases, such as asthma |
| 02/02/2006 | US20060025413 3-(arylamino)methylene-1,3-dihydro-2H-indol-2-ones as kinase inhibitors |
| 02/02/2006 | US20060025410 2,4-Pyrimidinediamine compounds and their uses |
| 02/02/2006 | US20060025403 Compounds useful as modulators of melanocortin receptors and pharmaceutical compositions comprising same |
| 02/02/2006 | US20060025396 Isophthalic acid derivatives as matrix metalloproteinase inhibitors |
| 02/02/2006 | US20060024804 Isoforms isolated and purified from mammalian colostrum |
| 02/02/2006 | US20060024792 G-protein coupled receptors |
| 02/02/2006 | US20060024306 Methods of treating and preventing colitis involving il-13 and nk-t cells |
| 02/02/2006 | US20060024293 Antibody for use in the treatment and prevention of sepsis, infections, autoimmune and graft-versus-host diseases; biodegradable, biocompatible polymer and human antibody, or an antigen-binding portion thereof, that dissociates from human TNF alpha |
| 02/02/2006 | US20060024267 TNFr/OPG-like molecules and uses thereof |
| 02/02/2006 | US20060024233 Use of biomolecular targets in the treatment and visualization of brain tumors |
| 02/02/2006 | CA2575272A1 Use of k-252a and kinase inhibitors for the prevention or treatment of hmgb1-associated pathologies |
| 02/02/2006 | CA2573543A1 N-phenylphosphoric acid triamides, method for the production thereof and their use as agents for regulating or inhibiting enzymatic urea hydrolysis |
| 02/01/2006 | EP1621548A2 Polypeptides, CDNAs encoding the same and utilization thereof |
| 02/01/2006 | EP1621540A1 Nitrogen-containing heterocyclic compounds and use thereof |
| 02/01/2006 | EP1621198A2 Substituted carbostyril derivatives as 5-HT 1A receptor subtype agonists |
| 02/01/2006 | EP1621195A2 The use of pyridinic NK-1 receptor antagonists for the treatment of brain, spinal or nerve injury |
| 02/01/2006 | EP1620096A2 Pellet formulations of acid-labile antiulcer benzimidazole compounds |
| 02/01/2006 | EP1620087A1 Azabicyclo derivatives as muscarinic receptor antagonists |
| 02/01/2006 | EP1619962A1 Composition for oral administration containing capsaicinoids |
| 02/01/2006 | EP1521535B1 Improved bulking agent composition |
| 02/01/2006 | EP1500654B1 Benzoxazinone derivatives, the preparation and use thereof as medicaments |
| 02/01/2006 | EP1487421B1 Pharmaceutical formulation for the active ingredient budesonide |
| 02/01/2006 | EP1476419B1 N-biphenylmethyl aminocycloalkanecarboxamide derivatives |
| 02/01/2006 | EP1463707A4 A group of novel anti-cancer compounds with specific structure |
| 02/01/2006 | EP1430144A4 METHODS OF USING 69039, A NOVEL HUMAN Na/Ca EXCHANGER FAMILY MEMBER |
| 02/01/2006 | EP1425281B1 Tricyclic CRF receptor antagonists |
| 02/01/2006 | EP1343492B1 Treatment of mucositis |
| 02/01/2006 | EP1235812B1 Pyrimidine derivatives as selective inhibitors of cox-2 |
| 02/01/2006 | EP1194409B1 Pyrazolidinol compounds |
| 02/01/2006 | EP1169336B1 Ent-steroids as selectively active estrogens |
| 02/01/2006 | EP1150675B1 A transdermal composition of an antivomiting agent and a preparation containing the same |
| 02/01/2006 | EP1133315B1 Antagonists of the alpha e beta 7 integrin as therapeutic agents for inflammatory diseases |
| 02/01/2006 | EP1131302B1 Substituted 4-amino-2-aryl-cyclopenta [d]pyrimidines, their production and use and pharmaceutical preparations containing the same |
| 02/01/2006 | EP1119563B1 Tetrahydrobenzazepine derivatives useful as modulators of dopamine d3 receptors (antipsychotic agents) |
| 02/01/2006 | EP1104289B1 New oral formulation for 5-ht4 agonists or antagonists |
| 02/01/2006 | EP1080078B1 Heterocyclic compounds and methods to treat cardiac failure and other disorders |
| 02/01/2006 | EP1064402B1 Antisense modulation of lfa-3 |
| 02/01/2006 | CN1729192A Optical resolution of (1-benzyl-4-methylpiperidin-3-yl) -methylamine and the use thereof for the preparation of pyrrolo 2,3-pyrimidine derivatives as protein kinases inhibitors |
| 02/01/2006 | CN1729009A Phosphoprotein preparations for bioactive metal ion delivery and teeth remineralisation |
| 02/01/2006 | CN1728997A Amorphous form of esomeprazole salts |
| 02/01/2006 | CN1728987A Edible phosphoprotein film |
| 02/01/2006 | CN1728946A Method of obtaining viable human liver cells, including hepatic stem/progenitor cells |
| 02/01/2006 | CN1727480A Gene of expressing regeneration enhancement factor of recombined human liver in full lenght, and method for preparing regeneration enhancement factor of recombined human liver in full length, and usag |
| 02/01/2006 | CN1727479A Gene of expressing regeneration enhancement factor of recombined human liver in full length, and method for preparing regeneration enhancement factor of recombined human liver in full length, and usag |
| 02/01/2006 | CN1727000A Chinese materia medica preparation for treating gastric disease |
| 02/01/2006 | CN1726986A Chinese traditional medicine for treating gastric disease, and preparation method |
| 02/01/2006 | CN1726978A Invigoration Chinese traditional medicine for treating kidney deficiency, and preparation method |
| 02/01/2006 | CN1726973A Chinese materia medica preparation for treating hepatitis b virus |
| 02/01/2006 | CN1726960A Combination of effective parts for curing chronic hepatitis, preparation and usage |
| 02/01/2006 | CN1726948A Medication for treating ascites of liver, cirrhosis of liver and liver cancer in early stage |
| 02/01/2006 | CN1726943A No cane sugar type tablet of remove stagnated food by using stamachics and preparation method |